Skip to main content

Table 2 PRO-CTCAE item intraclass correlation by tablet, IVRS and paper modes of administration

From: Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

PRO-CTCAE Item

ICC (95 % CI)

 

Mode Equivalence

Test – Retesta

 

Tablet vs. IVRS

Tablet vs. Paper

IVRS vs. Paper

Tablet vs. Tablet

Anxiety (F)

0.77 (0.68–0.83)

0.76 (0.67–0.83)

0.72 (0.61–0.79)

0.78 (0.68–0.85)

Anxiety (S)

0.75 (0.65–0.82)

0.72 (0.62–0.80)

0.73 (0.63–0.80)

0.70 (0.58–0.80)

Anxiety (I)

0.69 (0.58–0.77)

0.74 (0.64–0.81)

0.68 (0.57–0.77)

0.83 (0.75–0.89)

Constipation (S)

0.71 (0.60–0.79)

0.76 (0.66–0.83)

0.80 (0.73–0.86)

0.83 (0.74–0.89)

Decreased appetite (S)

0.73 (0.62–0.80)

0.80 (0.72–0.86)

0.82 (0.73–0.87)

0.81 (0.71–0.87)

Decreased appetite (I)

0.78 (0.69–0.84)

0.80 (0.72–0.86)

0.70 (0.60–0.79)

0.80 (0.71–0.87)

Fatigue, tiredness, or lack of energy (S)

0.74 (0.64–0.81)

0.76 (0.67–0.83)

0.74 (0.64–0.81)

0.77 (0.66–0.85)

Fatigue, tiredness, or lack of energy (I)

0.65 (0.53–0.75)

0.70 (0.59–0.79)

0.60 (0.46–0.70)

0.79 (0.69–0.86)

Insomnia (S)

0.83 (0.76–0.88)

0.94 (0.92–0.96)

0.79 (0.71–0.85)

0.65 (0.50–0.76)

Insomnia (I)

0.76 (0.67–0.83)

0.84 (0.77–0.89)

0.81 (0.74–0.87)

0.72 (0.59–0.81)

Loose or watery stools (F)

0.80 (0.73–0.86)

0.81 (0.74–0.87)

0.76 (0.67–0.83)

0.55 (0.38–0.69)

Mouth or throat sores (S)

0.82 (0.75–0.87)

0.87 (0.82–0.91)

0.71 (0.61–0.79)

0.82 (0.73–0.88)

Mouth or throat sores (I)

0.55 (0.41–0.67)

0.62 (0.48–0.72)

0.61 (0.47–0.71)

0.81 (0.72–0.87)

Nausea (F)

0.87 (0.81–0.91)

0.90 (0.85–0.93)

0.87 (0.82–0.91)

0.79 (0.70–0.86)

Nausea (S)

0.85 (0.78–0.89)

0.87 (0.82–0.91)

0.86 (0.80–0.90)

0.84 (0.76–0.89)

Numbness/tingling in hands/feet (S)

0.89 (0.85–0.92)

0.89 (0.84–0.92)

0.86 (0.81–0.91)

0.80 (0.70–0.86)

Numbness/tingling in hands/feet (I)

0.81 (0.73–0.86)

0.85 (0.79–0.90)

0.80 (0.73–0.86)

0.55 (0.37–0.68)

Pain (F)

0.90 (0.86–0.93)

0.93 (0.90–0.95)

0.91 (0.87–0.94)

0.83 (0.75–0.89)

Pain (S)

0.88 (0.83–0.92)

0.89 (0.85–0.92)

0.86 (0.81–0.90)

0.82 (0.73–0.88)

Pain (I)

0.77 (0.68–0.84)

0.83 (0.77–0.88)

0.77 (0.68–0.83)

0.84 (0.76–0.89)

Sad or unhappy feelings (F)

0.77 (0.68–0.83)

0.80 (0.72–0.85)

0.76 (0.67–0.83)

0.73 (0.61–0.81)

Sad or unhappy feelings (S)

0.77 (0.69–0.84)

0.79 (0.71–0.85)

0.79 (0.71–0.85)

0.63 (0.48–0.75)

Sad or unhappy feelings (I)

0.69 (0.58–0.78)

0.70 (0.59–0.78)

0.72 (0.61–0.80)

0.76 (0.65–0.84)

Shortness of breath (S)

0.85 (0.79–0.89)

0.87 (0.82–0.91)

0.90 (0.85–0.93)

0.70 (0.56–0.80)

Shortness of breath (I)

0.84 (0.77–0.89)

0.73 (0.63–0.81)

0.72 (0.61–0.80)

0.66 (0.52–0.77)

Vomiting (F)

0.82 (0.75–0.87)

0.96 (0.94–0.97)

0.87 (0.82–0.91)

0.81 (0.72–0.88)

Vomiting (S)

0.82 (0.75–0.87)

0.92 (0.88–0.94)

0.83 (0.76–0.88)

0.79 (0.70–0.86)

  1. Note: The mode equivalence of the presence/absence item assessing rash was evaluated with Kappa statistics and results are reported in the text
  2. Abbreviations: PRO-CTCAE Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events, F Frequency, S Severity, I Interference, ICC Intraclass Correlation Coefficient, CI Confidence Interval, IVRS Interactive Voice Response System
  3. aTest-retest data were obtained from the validation study [3] (see Methods)